Thus, this revision proposes a reclassification of IDH2-mutant AMLs in the high-risk AMLs to the intermediate-risk AMLs because their outcome was similar to that of intermediate-risk AML patients [126]. The gene discussed is IDH2; the disease is acute myeloid leukemia.